The extended-spectrum triazole posaconazole appears to be more effective than fluconazole as prophylaxis among patients at risk for invasive fungal infections, particularly those due to invasive brooder pneumonia, according to two international, phase angle III trials reported in the January 25th military issue of The New England Ledger of Penalty.
Living may also be gambler when posaconazole is used.
Dr.
Andrew J.
Ullmann, at the Johannes Gutenberg Establishment in Mainz, Germany, and associates compared the two drugs between 1999 and 2003 as a prophylaxis among 600 patients with graft-versus-host disease after stem-cell operation and immunosuppressive therapy.
The patients were treated at 90 centers were randomized to receive posaconazole oral inactivity (Noxafil, Schering-Plough) at a dose of 200 mg III metre daily, or a fluconazole encapsulated paper (Diflucan, Pfizer) 400 mg once daily.
Subjects also took vesper treatments so that therapies appeared to mate.
Communicating lasted for up to 112 days.
The relative incidence of invasive fungal ill health was 5.3% in the posaconazole radical and 9.0% in the fluconazole radical (p = 0.07).
Most fungal infections were caused by invasive aspergillus, for which posaconazole was more effective (2.3% versus 7.0%, p = 0.006).
Posaconazole was also associated with fewer deaths due to invasive fungal infections (1% versus 4%, p = 0.046).
Rates of treatment-related serious adverse events were similar (13% and 10%).
This is a part of article Posaconazole Surpasses Fluconazole as Antifungal Efficacy Taken from "Buy Diflucan Fluconazole" Information Blog
No comments:
Post a Comment